Literature DB >> 35246769

Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of cytoreductive surgery in the management of progressive glioblastoma in adults.

Hayes H Patrick1, Jonathan H Sherman2, J Bradley Elder3, Jeffrey J Olson4.   

Abstract

QUESTION: In patients with previously diagnosed glioblastoma who are suspected of experiencing progression, does repeat cytoreductive surgery improve progression free survival or overall survival compared to alternative interventions? TARGET POPULATION: These recommendations apply to adults with previously diagnosed glioblastoma who are suspected of experiencing progression of the neoplastic process and are amenable to surgical resection. RECOMMENDATION: Level II: Repeat cytoreductive surgery is recommended in progressive glioblastoma patients to improve overall survival.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cytoreductive surgery; Glioblastoma; Recurrent

Mesh:

Year:  2022        PMID: 35246769     DOI: 10.1007/s11060-021-03881-w

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  1 in total

1.  Comparison of 5-aminolevulinic acid and sodium fluorescein for intraoperative tumor visualization in patients with high-grade gliomas: a single-center retrospective study.

Authors:  Rasmus W Hansen; Christian B Pedersen; Bo Halle; Anders R Korshoej; Mette K Schulz; Bjarne W Kristensen; Frantz R Poulsen
Journal:  J Neurosurg       Date:  2019-10-04       Impact factor: 5.115

  1 in total
  1 in total

Review 1.  Recurrent Glioblastoma Treatment: State of the Art and Future Perspectives in the Precision Medicine Era.

Authors:  Augusto Leone; Antonio Colamaria; Nicola Pio Fochi; Matteo Sacco; Matteo Landriscina; Giovanni Parbonetti; Matteo de Notaris; Giulia Coppola; Elena De Santis; Guido Giordano; Francesco Carbone
Journal:  Biomedicines       Date:  2022-08-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.